Mural Oncology (NASDAQ:MURA) Given Hold Rating at Jones Trading

Jones Trading restated their hold rating on shares of Mural Oncology (NASDAQ:MURA) in a research note published on Tuesday,Benzinga reports.

Separately, HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Mural Oncology in a research report on Wednesday, March 12th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Mural Oncology Trading Down 61.6 %

NASDAQ:MURA opened at $1.47 on Tuesday. Mural Oncology has a 1 year low of $1.37 and a 1 year high of $5.12. The stock has a 50-day moving average price of $3.87 and a two-hundred day moving average price of $3.61. The stock has a market cap of $25.33 million, a price-to-earnings ratio of -0.16 and a beta of 3.66.

Mural Oncology (NASDAQ:MURA) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($2.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same quarter last year, the business posted ($3.57) earnings per share. Sell-side analysts forecast that Mural Oncology will post -7.54 earnings per share for the current year.

Hedge Funds Weigh In On Mural Oncology

Several hedge funds have recently made changes to their positions in the business. Commerce Bank bought a new stake in shares of Mural Oncology in the third quarter worth $39,000. FMR LLC increased its stake in Mural Oncology by 124.7% in the 3rd quarter. FMR LLC now owns 20,580 shares of the company’s stock valued at $64,000 after buying an additional 11,423 shares during the last quarter. Jane Street Group LLC bought a new stake in Mural Oncology during the 4th quarter worth about $68,000. Two Sigma Advisers LP acquired a new position in shares of Mural Oncology during the 4th quarter worth about $84,000. Finally, Bridgeway Capital Management LLC bought a new position in shares of Mural Oncology in the 4th quarter valued at about $94,000. 80.21% of the stock is owned by institutional investors.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.